A global study of volrustomig (MEDI5752) for participants with unresected locally advanced head and neck squamous cell carcinoma following definitive concurrent chemoradiotherapy - eVOLVE-HNSCC

Exclusion Criteria

• • Histologically/cytologically confirmed head and neck cancer of any other primary anatomic location in the head and neck not specified in the inclusion criteria including participants with squamous cell carcinoma of unknown primary or non-squamous histologies (eg, nasopharynx or salivary gland). Participants with >1 primary tumors are not eligible for the study.
• • Participants with any of the following:
• (a) Residual disease that needs further treatment with curative intent after definitive cCRT administration;
• (b) LA-HNSCC that was resected before definitive cCRT
• (c) LA-HNSCC that was treated and is recurrent at the time of screening
• • Participants who have received radiotherapy (RT) alone as definitive local therapy for LA-HNSCC.
• • Receipt of the last dose of anticancer therapy (chemotherapy and/or RT) > 12 weeks (84 days) prior to randomization.